Literature DB >> 1322154

Overexpression of multiple oncogenes related to histological grade of astrocytic glioma.

J M Orian1, K Vasilopoulos, S Yoshida, A H Kaye, C W Chow, M F Gonzales.   

Abstract

The expression of the c-erbB-1, c-myc, Ha/N-ras and c-fos oncogenes was investigated in 62 astrocytomas of low, intermediate and high grades by immunogold silver histochemistry. Elevated expression of c-erbB-1 was observed in 95%, 48% and 86% of low, intermediate and high grade tumours respectively, c-myc in 5%, 33% and 76% respectively, Ha/N-ras in 0, 43% and 71% respectively and c-fos in 55%, 48% and 52% respectively. Controls included normal brain and tumour sections immunoreacted with pre-immune serum or with antisera absorbed with synthetic peptides. Analysis of co-overexpression revealed that low grade tumours co-overexpressed a maximum of two of these genes, intermediate grade tumours a maximum of three of these genes, while co-overexpression of all four genes was observed in some high grade tumours. Co-overexpression of c-erbB-1 and c-fos was frequently observed in low grade astrocytomas and may be predictive of non-progression. On the other hand, there was a statistically significant increase in the number of tumours overexpressing Ha/N-ras or c-myc with increasing grade of tumour, suggesting that overexpression of these two oncogenes may be indicative of progression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322154      PMCID: PMC1977917          DOI: 10.1038/bjc.1992.225

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas.

Authors:  M A Gerosa; D Talarico; C Fognani; E Raimondi; M Colombatti; G Tridente; L De Carli; G Della Valle
Journal:  J Natl Cancer Inst       Date:  1989-01-04       Impact factor: 13.506

3.  Polysomy of chromosome 7 is correlated with overexpression of the erbB oncogene in human glioblastoma cell lines.

Authors:  W Henn; N Blin; K D Zang
Journal:  Hum Genet       Date:  1986-09       Impact factor: 4.132

4.  Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma.

Authors:  J Trent; P Meltzer; M Rosenblum; G Harsh; K Kinzler; R Mashal; A Feinberg; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

Review 5.  The neu (c-erbB-2) oncogene.

Authors:  H C Maguire; M I Greene
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

6.  Proto-oncogene analyses in brain tumors.

Authors:  M Fujimoto; P J Sheridan; Z D Sharp; F J Weaker; S Kagan-Hallet; J L Story
Journal:  J Neurosurg       Date:  1989-06       Impact factor: 5.115

7.  Quantification of the c-myc oncoprotein in human glioblastoma cells and tumor tissue.

Authors:  H H Engelhard; A B Butler; K D Bauer
Journal:  J Neurosurg       Date:  1989-08       Impact factor: 5.115

8.  Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme.

Authors:  L T Malden; U Novak; A H Kaye; A W Burgess
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

9.  Epidermal growth factor receptors in intracranial and breast tumours: their clinical significance.

Authors:  R A Hawkins; E Killen; I R Whittle; W J Jack; U Chetty; R J Prescott
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

10.  Expression of growth factor receptors in human brain tumours.

Authors:  N L Tuzi; D J Venter; S Kumar; S L Staddon; N R Lemoine; W J Gullick
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

View more
  21 in total

1.  mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells.

Authors:  Federico Bolognani; Anne-Isabelle Gallani; Lena Sokol; David S Baskin; Nicole Meisner-Kober
Journal:  J Neurooncol       Date:  2011-09-21       Impact factor: 4.130

2.  Infrequency of p53 gene mutations in ependymomas.

Authors:  K L Fink; E J Rushing; S C Schold; P D Nisen
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

3.  Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.

Authors:  Fanny Burel-Vandenbos; Laurent Turchi; Maxime Benchetrit; Eric Fontas; Zoe Pedeutour; Valérie Rigau; Fabien Almairac; Damien Ambrosetti; Jean-François Michiels; Thierry Virolle
Journal:  Neuro Oncol       Date:  2013-08-09       Impact factor: 12.300

4.  Off-target effect of the BMI1 inhibitor PTC596 drives epithelial-mesenchymal transition in glioblastoma multiforme.

Authors:  Anthony Flamier; Mohamed Abdouh; Rimi Hamam; Andrea Barabino; Niraj Patel; Andy Gao; Roy Hanna; Gilbert Bernier
Journal:  NPJ Precis Oncol       Date:  2020-01-06

5.  EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas.

Authors:  Parsa Erfani; Jessica Tome-Garcia; Peter Canoll; Fiona Doetsch; Nadejda M Tsankova
Journal:  Epigenetics       Date:  2015-05-21       Impact factor: 4.528

6.  The Polycomb Repressive Complex 1 Protein BMI1 Is Required for Constitutive Heterochromatin Formation and Silencing in Mammalian Somatic Cells.

Authors:  Mohamed Abdouh; Roy Hanna; Jida El Hajjar; Anthony Flamier; Gilbert Bernier
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

7.  Stabilization of c-myc protein in human glioma cells.

Authors:  H Shindo; E Tani; T Matsumuto; T Hashimoto; J Furuyama
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.

Authors:  Fanny Burel-Vandenbos; Maxime Benchetrit; Catherine Miquel; Denys Fontaine; Romane Auvergne; Christine Lebrun-Frenay; Nathalie Cardot-Leccia; Jean-François Michiels; Veronique Paquis-Flucklinger; Thierry Virolle
Journal:  J Neurooncol       Date:  2010-07-24       Impact factor: 4.130

9.  MMI-166, a selective matrix metalloproteinase inhibitor, promotes apoptosis in human pancreatic cancer.

Authors:  Chong-Chong Gao; Ben-Gang Gong; Jun-Ben Wu; Pi-Guang Cheng; Huai-Yong Xu; De-Kun Song; Fei Li
Journal:  Med Oncol       Date:  2014-12-04       Impact factor: 3.064

10.  Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells.

Authors:  H H Engelhard; R J Homer; H A Duncan; J Rozental
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.